What's new?

Success of the capital increase with pre-emptive subscription rights: €7.3 million raised to finance the Prima System PRIMAvera pivotal study                       Paris, 6 July 2020 – 7.00 a.m. CET - Pixium Vision (Euronext Growth Paris - FR0011950641 - ALPIX) (“Pixium Vision” or the “Company”), a company that dev...

- Dr Moses is internationally recognized as a leading CEO and Chairman of life science companies - Dr Moses led the rapid growth of Ablynx from a platform technology to a fully integrated biopharmaceutical company prior its acquisition by Sanofi - Appointment adds momentum and validation to Sensorion assets and str...

PARIS, FRANCE / ACCESSWIRE / July 2, 2020 -- MastOR, a medical device company developing a surgical robot for laparoscopy assistance, announced today a €3M equity round through a seed investment from the Sofinnova Partners MD Start III Fund, as well as an additional €1.9M in non-dilutive funding through the i-Nov I...

Investments in innovative medical devices follow the fund’s initial closing in May 2019   PARIS, France – July 2, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the second investment from its MD Start III Fund, a medtech accelerator...

DJ Redx Pharma plc Proposed financing of $30m and notice of GM   TIDMREDX RNS Number : 4498R Redx Pharma plc 30 June 2020 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULA TION (596/2014). UPON THE PUBLICATION ...

This collaboration aims to enable ELSAN physicians to transform their ideas for innovation into clinically-validated devices and to contribute their expertise to new projects. June 25, 2020 - PARIS, France - ELSAN, a leader in the private hospital sector in France, announces a strategic partnership with the Sofinno...

• U.S. commercialization expected to begin in the first half of 2021   • Continues positive momentum for Mainstay, with increasing commercial footprint in Europe and expected launch in Australia in early 2021   June 22, 2020 02:00 AM Eastern Daylight Time DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc (“Mai...

June 16, 2020 at 8:20 PM EDT   SANTA CLARA, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced the pricing of its public offering of 1,700,000 shares of its common stock at a price to the public of $45.75 per share.

Daix (France), June 15, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced positive toplin...

Company announces strategic collaboration with SR-Tiget   MILAN, Italy – June 15, 2020 -- Epsilen Bio, a biotechnology company developing transformative therapies for patients affected by underserved medical conditions through stable epigenetic silencing of genes involved in pathological processes, announced today ...